about
Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis CLiving donor liver transplantation for patients immunized against human leukocyte antigen.Outcome of liver transplantation for recipients with hepatitis B and hepatitis C virus coinfection: analysis of the UNOS data.Long-term outcome of living donor liver transplantation for primary biliary cirrhosis.Antiviral treatment for hepatitis C virus infection after liver transplantation.Primary sclerosing cholangitis as an intractable diseaseImpact of early reoperation following living-donor liver transplantation on graft survival.Perceptions of post-transplant recidivism in liver transplantation for alcoholic liver disease.Liver transplantation in HCV/HIV positive patients.Living donor liver transplantation using sensitized lymphocytotoxic crossmatch positive graftDonor evaluation and hepatectomy for living-donor liver transplantation.Recurrence of cholestatic liver disease after living donor liver transplantationDonor quality of life after living donor liver transplantation: a prospective study.Living donor liver transplantation for hepatocellular carcinoma: the Japanese experience.Living-donor liver transplantation for autoimmune hepatitis and autoimmune hepatitis-primary biliary cirrhosis overlap syndrome.New-onset diabetes mellitus developing in Asian adult living donor liver transplant recipients: a single-center experience.Safety and efficacy of cryopreserved homologous veins for venous reconstruction in pancreatoduodenectomy.Interleukin-2 receptor antagonist immunosuppression and consecutive viral management in living-donor liver transplantation for human immunodeficiency virus/hepatitis C-co-infected patients: a report of 2 cases.One-year extended, monthly vaccination prophylaxis combined with hepatitis B immune globulin for hepatitis B after liver transplantation.Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience.Basiliximab as therapy for acute rejection after liver transplantation for hepatitis C virus cirrhosis.Noninvasive estimation of hepatic steatosis in living liver donors: usefulness of visceral fat area measurement.Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma.Portal uptake function in veno-occlusive regions evaluated by real-time fluorescent imaging using indocyanine green.Section 4. Further expanding the criteria for HCC in living donor liver transplantation: the Tokyo University experience.Portal vein complications after adult-to-adult living donor liver transplantation.Living donor liver transplantations in HIV- and hepatitis C virus-coinfected hemophiliacs: experience in a single center.Double-dose double-phase use of second generation hepatitis B virus vaccine in patients after living donor liver transplantation: Not an effective measure in transplant recipients.Identification of veno-occlusive regions in a right liver graft after reconstruction of vein segments 5 and 8: application of indocyanine green fluorescence imaging.Real-time identification of liver cancers by using indocyanine green fluorescent imaging.An analysis of the OPTN/UNOS Liver Transplant Registry.Prevention of renal impairment by continuous infusion of human atrial natriuretic peptide after liver transplantation.De novo malignancies after adult-to-adult living-donor liver transplantation with a malignancy surveillance program: comparison with a Japanese population-based study.Positive lymphocytotoxic crossmatch does not adversely affect survival in living donor liver transplantation.Small-for-size syndrome and transjugular intrahepatic portosystemic shunt.Should we promote "increasing donor body weight to prevent small-for-size syndrome in living donor liver transplantation"?Discrepancy between estimated and actual weight of partial liver graft from living donors.Outcomes after living donor liver transplantation for acute liver failure in Japan: results of a nationwide survey.Systematic grading of surgical complications in live liver donors according to Clavien's system.
P50
Q31153267-9E2B0004-0671-4CA4-9FB4-6D7C5FAC5CC2Q33400192-B827E6B1-9B09-41F8-95E7-722EBFC2AAE4Q33990119-7F22FE03-3148-4CE2-9D48-C58A5708F32AQ34216929-671D78BF-7F5C-460D-B7DF-458BDEB6DE88Q34340293-3E8AB792-8CAA-4369-8711-467AB144C267Q34377975-B563021C-5A9C-48B1-9790-B2E1A9B2B081Q34512705-5A947584-9599-4775-A1E2-778B4C7E9A7FQ34567968-7ECB4197-201B-4683-9BE5-31C316137584Q34640985-D06BAF5D-23EB-4A98-B576-97E2A603C402Q35911619-C2BA0F86-0F6B-4242-9EB3-FAD551AF1E69Q37130073-5D4DE58A-2269-4E4E-9CE3-6072130F6A41Q37262983-8AF8B00E-A7FC-431B-9C6B-F887E60DA4D9Q37806128-015BA9B0-6802-4EE4-8ACF-284C083325B4Q37972811-14BE131E-721B-4B08-8472-465ECA0E44AEQ38006773-79E003AF-815E-4258-B4A0-DCDD5E1C1240Q39438721-9BA3DBC5-6747-4D2B-BC19-F96DEBCDFD0FQ40546788-BD182D02-A973-4A57-B749-57E39696F8D2Q40873539-76763F96-FE52-43BF-A112-D5B1D3B77E94Q42146642-10EE3818-89DC-4898-965F-32684A228325Q42183060-49A4FE12-0F5E-4CB3-ABD2-844A9464AEE8Q42993706-299CAD2F-DF06-4B9E-8224-8B146605E49FQ43036827-8FE8E864-674C-4691-8DD1-E82A4D29F122Q43288500-0DC6EBCF-B1D3-4F37-905E-A4ECEB9BA49DQ43714851-8522EBF1-63CB-4143-A977-F9E201D27133Q44289395-D577C838-E24B-43B2-BEA7-5EB7515FDFA5Q44797748-C54AEEDF-84E4-45FE-9B19-224CF2BD9B43Q44936553-61876F72-197F-41A9-A176-AC8A184911EEQ45366386-C3EB7940-7F24-4559-8DE9-8D87A33A482AQ45391722-81867C4B-BD4F-4BDA-9AAB-64107F40F90BQ45949106-CF99F138-52D4-42BF-BF0D-BFD9C2B5D0A4Q46072043-9944F91B-E846-4339-BA65-AD3F96B55B97Q46456122-0F3A2301-B8CC-4C3B-BC70-F3393A1BEA07Q46797347-38A5F82E-7599-41A8-8238-48774B907C42Q46890570-8246E79B-AAC6-4066-92E8-1771F4718EB7Q46934550-2FFB930B-2DA0-4D08-8026-879888CD800BQ47271268-A73D5B88-1040-48AA-9C02-119AC85D8E22Q47370093-229E09D1-F2C1-4B38-81F1-86395E29C302Q47388816-636CF1D9-015F-4055-9144-A815C4329B5BQ47779037-EE891218-289F-4D03-9882-AE381BF518E3Q48647334-E9B439C2-6E87-414E-9A6F-86EA4013C5BF
P50
name
Sumihito Tamura
@en
type
label
Sumihito Tamura
@en
prefLabel
Sumihito Tamura
@en